🤝 AstraZeneca and Bristol Myers Squibb were reportedly exploring a ~$400B megamerger, but a senior source later said no discussions were ongoing, cooling speculation over one of pharma’s largest potential combinations. ✂️ Pfizer expanded its cost-cutting program, targeting another $1B in savings, bringing planned total reductions to $6.7B as it offsets declining COVID revenues. 🎗️ Pharmanovia licensed senaparib across 66 countries for up to €423.5M, gaining a near-market PARP inhibitor for ovarian cancer that reduced progression or death risk by 57% in Phase 3.
🤝
🧠 Supernus Pharmaceuticals, Inc. and Indivior will merge to create a CNS-focused company with roughly $2B in combined 2025 revenue.
📊 Novo Nordisk raised its 2026 sales and profit outlook after stronger Q2 earnings, though shares fell as pricing pressure and softer-than-expected Wegovy pill uptake concerned investors.
📊 Eli Lilly and Company’s Zepbound and Mounjaro sales surged past expectations in Q2.
💰 Attovia Therapeutics raised $289M in its IPO, becoming the 12th biotech this year to raise at least $250M and extending 2026’s strong public-market reopening.
🫁 Expedition Therapeutics raised $115M Series B to advance a Fosun Pharma-licensed lung disease drug;
🟢 FDA approved Moderna’s mFLUSIVA, the world’s first mRNA seasonal flu vaccine, completing a dramatic regulatory turnaround after the agency initially declined to review the product.
📊 Merck KGaA, Darmstadt, Germany raised its annual sales and profitability forecasts again after reporting stronger second-quarter performance.
📊 Viatris posted 5% Q2 revenue growth to $3.8B, supported by strong performance in China and newer products across developed markets.
✅ FDA granted accelerated approval to Replimune’s TUDRIQEV plus nivolumab in advanced melanoma after anti-PD-1 progression.
📊 Insmed Incorporated beat Q2 expectations as ARIKAYCE and Brinsupri drove respiratory franchise growth, strengthening investor confidence in its commercial and pipeline momentum.
🟢 FDA approved Takedaa’s Orzeyful, clearing the way for a new orexin-based sleep drug expected to compete in a potentially multibillion-dollar market.
💰 LifeMine Therapeutics raised $263M to advance a fungi-derived immunosuppressive drug designed as a potentially safer option for preventing organ transplant rejection.
💰 Braveheart Bio raised more than $382M in its IPO, adding to a wave of large 2026 biotech listings and funding development of cardiovascular medicines.
💰 Latigo Biotherapeutics, Inc. raised nearly $350M in its IPO to advance non-opioid ion-channel pain drugs that could compete with programs from Vertex and Lilly.
🤝 Tarsus Pharmaceuticals, Inc. will acquire Alkeus Pharmaceuticals, Inc. for up to $800M, gaining gildeuretinol, a potential treatment for Stargardt disease;
❌ GSK discontinued camlipixant after two Phase 3 chronic cough trials showed limited efficacy, ending a major respiratory opportunity from the company’s $2B acquisition.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.